Patrick Kelly MD

Patrick is a board-certified paediatric haematologist/oncologist with 35 years of clinical practice and research experience, including 15 years of academic and clinical leadership in haematology/oncology, followed by 20 years of global industry experience in early- and late-stage drug development with targeted anti-cancer agents.

Patrick has served key roles in leading pharmaceutical companies including Takeda Oncology, Infinity Pharmaceuticals and Pfizer where he played integral parts in advancing therapies and shaping the landscape of medical innovation. He has successfully led clinical activities for multiple investigational new drug (IND) submissions and Food and Drug Administration (FDA) approvals. This includes the early phase ADC (Besponsa®) and small molecule (Daurismo®) programs in lymphoma/leukaemia whilst at Pfizer, and the development for Copiktra® in lymphoma/leukaemia during his time at Infinity Pharmaceuticals

Most recently he served as CMO at Forma Therapeutics (now part of Novo Nordisk) where he led the overall clinical strategy and progression of multiple development programs. Notably Patrick oversaw the development of Rezlidhia®, which is now approved for the treatment of IDH1-mutated acute myeloid leukaemia.

Patrick obtained his M.D. from University of Maryland School of Medicine.